Breast Cancer | Specialty

Dr. Nagendran on Family History, BRCA Status, and Risk

January 20th 2014

Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, discusses a study looking at patients' family history, BRCA mutation status, and breast cancer risk.

Dr. Piccart on a 4-Year Follow-Up of the NeoALTTO Trial

January 14th 2014

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an update on a four-year follow-up analysis of the NeoALTTO trial.

Fisher's Respect for Scientific Methods Propelled Landmark Advances

January 10th 2014

When Bernard Fisher, MD, first became involved in breast cancer research, the only treatment option available to patients was the radical mastectomy, a horribly disfiguring surgery that had been the undisputed standard of care since the late 1800s

Dr. Gradishar on Endocrine Therapy in Early Stage Disease

January 10th 2014

William J. Gradishar, MD, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the treatment of early stage breast cancer with endocrine therapy and considerations following resistance.

Dr. O'Regan on Breast Cancer Endocrine Therapy Resistance

January 8th 2014

Ruth M. O'Regan, MD, director of Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses resistance to endocrine therapy in patients with metastatic, hormone receptor-positive breast cancer.

Novel Tomography System May Help Guide Therapy in Early Breast Cancer

January 8th 2014

Diffuse optical tomography (DOT) is a novel, fast, safe, and low-cost technique that uses near-infrared light to provide three-dimensional data on tissue vascularity without the use of radiation.

Jerry Lanchbury, PhD, Describes Myriad's HRD Test

January 3rd 2014

Jerry Lanchbury, PhD, Chief Scientific Officer, Myriad Genetics, Inc., describes the HRD (homologous recombination deficiency) test.

Significant Changes to Reimbursement Rates in Breast Cancer for 2014

December 31st 2013

Although the changeover to using ICD-10 billing codes won't be mandatory until October 1, 2014, there are many coding changes to consider starting on January 1. Specifically, the reimbursement rate for some genetic testing and imaging involving breast cancer will see significant changes.

PI3K-Targeting Agents May Help Overcome Resistance in Breast Cancer Treatment

December 20th 2013

Through a variety of research roles, Sara Hurvitz, MD, is exploring novel targeted therapies for the treatment of breast cancer, including developing and implementing clinical trials. Her interests include the phosphatidylinositol 3-kinase (PI3K) signaling pathway.

Managing Bone Health in Advanced Lung Cancer

December 19th 2013

Managing Bone Health in Breast Cancer

December 19th 2013

Managing Bone Health in Prostate Cancer

December 19th 2013

FALCON Trial Compares Two Types of Endocrine Therapy

December 19th 2013

The question of whether fulvestrant (Faslodex) should be moved forward in the treatment timeline for postmenopausal women with advanced, hormone receptor (HR)-positive breast cancer is being evaluated in an international, randomized phase III trial.

Dr. Neumayer Discusses the POWER PIINC Trial

December 18th 2013

Leigh A. Neumayer, MD, discusses the POWER PIINC trial, a study to measure the preoperative window of endocrine therapy.

Dr. Turner Discusses the PALOMA-3 Trial

December 17th 2013

Nicholas Turner, PhD, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

Dr. Garner Discusses the myRisk Hereditary Cancer Test

December 16th 2013

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.

Postneoadjuvant Bisphosphonate Benefits in Breast Cancer Linked to Age, Menopausal Status

December 16th 2013

Postneoadjuvant bisphosphonate therapy in women with residual invasive disease following chemotherapy for primary breast cancer does not improve clinical outcomes, according to an interim analysis of a large phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.

Dr. Esserman Discusses the I-SPY 2 Trial

December 16th 2013

Laura J. Esserman, MD, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

Dr. Brenner on the Link Between Breast Cancer and Obesity

December 13th 2013

Andrew J. Brenner, MD, PhD, from the Cancer Therapy Research Center, discusses the link between obesity and breast cancer outcomes.

Dr. Julie Gralow Discusses the SWOG S0500 Trial

December 13th 2013

Julie R. Gralow, MD, from the Seattle Cancer Care Alliance, discusses the SWOG S0500 trial, which evaluated different therapies for patients with metastatic breast cancer who had elevated circulating tumor cell levels.